1-(5-溴-2-氟苯基)乙酮 | 198477-89-3

• 物质功能分类: 有机原料 - 酮类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(5-溴-2-氟苯基)乙酮
• 中文别名: 5'-溴-2'-氟苯乙酮；2'-氟-5'-溴苯乙酮；乙酮,1-(5-溴-2-氟苯基)-；2-氟-5-溴苯乙酮
• 英文名称: 1-(5-bromo-2-fluorophenyl)ethan-1-one
• 英文别名: 1-(5-Bromo-2-fluoro-phenyl)-ethanone；1-(5-bromo-2-fluorophenyl)-1-ethanone；5-bromo-2-fluoroacetophenone；1-(5-Bromo-2-fluorophenyl)ethanone
• CAS: 198477-89-3
• 化学式: C₈H₆BrFO
• mdl: MFCD11226880
• 分子量: 217.037
• InChiKey: XNRQIHIOKXQSPG-UHFFFAOYSA-N

物化性质

• 熔点：
  42 °C
• 沸点：
  251℃
• 密度：
  1.535
• 闪点：
  106℃

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2914700090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
5’-Bromo-2’-fluoroacetophenone
Product Name:
Synonyms: 1-(5-Bromo-2-fluorophenyl)ethanone

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
5’-Bromo-2’-fluoroacetophenone
Ingredient name:
CAS number: 198477-89-3

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H6BrFO
Molecular weight: 217.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

应用

1-(5-溴-2-氟苯基)乙酮是一种化工中间体，在香料、药品、树脂和催泪瓦斯等化工领域的生产中发挥着极为重要的作用。

合成方法

在干燥的烧瓶中，将5-溴-2-氟-N-甲氧基-N-甲基苯甲酰胺（3.73 g，14.2 mmol）溶解于四氢呋喃（24 ml），然后滴加甲基氯化镁（3M四氢呋喃溶液，5.69 ml，17 mmol）。完全加入后，将反应混合物加热至回流。20分钟后，在冰浴中用饱和氯化铵溶液（25 ml）猝灭白色悬浮液。随后，用乙酸乙酯（50 ml）稀释，分离水层并用乙酸乙酯重新提取一次（50 ml）。合并的有机层用盐水（20 ml）洗涤，然后用硫酸钠干燥，最后减压蒸发。最终得到1-(5-溴-2-氟苯基)乙酮淡黄色固体（2.6 g），产率为84%，Rf值为0.55（硅胶；洗脱液：庚烷/乙酸乙酯=4/1）。

反应信息

• 作为反应物：
  描述：

  1-(5-溴-2-氟苯基)乙酮 在 盐酸 、 硫酸 、 氨 、 水 、 氯化铵 作用下， 以 甲醇 为溶剂， 反应 162.0h， 生成 (RS)-2-amino-2-(5-bromo-2-fluoro-phenyl)-propionic acid methylester
  参考文献：
  名称：

  合理设计和合成氨基哌嗪酮类β-分泌酶（BACE）抑制剂

  摘要：

  通过合理设计鉴定了BACE的氨基哌嗪酮抑制剂。基于结构的设计指导思想优先级排序和初始外消旋命中数18a显示出良好的活动性。修饰修饰和手性分离产生了40 nM抑制剂（-）-37，它在体内显示淀粉样β肽减少。18a的晶体结构显示出一种结合模式，该结合模式是由与催化天冬氨酸二联体相互作用以及联芳基酰胺修饰物朝S1和S3口袋分布而驱动的。

  DOI：

  10.1016/j.bmcl.2011.10.050
• 作为产物：
  描述：

  5-溴-2-氟苯甲醛 在 manganese(IV) oxide 作用下， 以 1,4-二氧六环 为溶剂， 反应 5.0h， 生成 1-(5-溴-2-氟苯基)乙酮
  参考文献：
  名称：

  新型多取代的Pyridin-3-amine衍生物作为多靶点蛋白激酶抑制剂的设计，合成和药理评价，用于治疗非小细胞肺癌

  摘要：

  设计，合成和评估了一系列新颖的吡啶-3-胺衍生物，作为多靶点蛋白激酶抑制剂用于非小细胞肺癌（NSCLC）的治疗。首先通过计算机筛选针对成纤维细胞生长因子受体（FGFR）的命中1，随后通过体外实验对其进行了验证。然后研究其类似物的结构-活性关系（SAR），以提供新型FGFR抑制剂2a - 2p和3a - 3q。其中3m对FGFR1、2和3表现出有效的抑制作用。有趣的是，化合物3m不仅抑制FGFR过度激活的癌细胞中不同致癌形​​式的各种磷酸化和下游信号传导，而且还显示出对数种其他NSCLC相关癌基因激酶（包括RET，EGFR，EGFR / T790M / L858R，DDR2和ALK）的纳摩尔水平抑制作用。最后，3m的体内药理学评估显示具有良好药代动力学特征的NCI-H1581 NSCLC异种移植物具有显着的抗肿瘤活性（TGI = 66.1％）。

  DOI：

  10.1021/acs.jmedchem.7b00076

文献信息

• Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith
  申请人：D'Sidocky Neil R.

  公开号：US20080242694A1

  公开（公告）日：2008-10-02

  Provided herein are Heterocyclic Compounds having the following structure: wherein R 1 , R 2 , X, Y and Z are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heterocyclic Compound to a patient in need thereof.

  本文提供具有以下结构的杂环化合物： 其中R1、R2、X、Y和Z如本文所定义，包含有效量杂环化合物的组合物，以及治疗或预防癌症、炎症性疾病、免疫疾病、代谢性疾病以及通过给予患者需要的有效量杂环化合物来抑制激酶途径治疗或预防的疾病的方法。
• [EN] PYRAZOLOSPIROKETONE ACETYL-C0A CARBOXYLASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PYRAZOLOSPIROCÉTONE ACÉTL-COA CARBOXYLASE
  申请人：PFIZER

  公开号：WO2009144554A1

  公开（公告）日：2009-12-03

  The invention provides compounds of Formula (1) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of acetyl-CoA carboxylase enzyme(s) in an animal.

  本发明提供了式(1)的化合物或所述化合物的药用可接受盐，其中R1、R2和R3如本文所述；其药物组合物；以及用于治疗通过抑制动物中的乙酰辅酶A羧化酶酶活性来调节的疾病、病症或障碍的使用方法。
• [EN] HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF TNF ALPHA<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILES EN TANT QUE MODULATEURS DU TNF ALPHA
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2017023905A1

  公开（公告）日：2017-02-09

  Disclosed are compounds of Formula (I) or a salt thereof, wherein: A is CR1 or N; B is CR3 or N; D is CR4 or N; L1 is -(CR7R7)m-; L2 is -(CR7R7)n-; and X, Z, R1, R2, R3, R4, R5,and R6 are define herein. Also disclosed are methods of using such compounds as modulators of TNFα, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

  披露了公式(I)化合物或其盐，其中：A是CR1或N；B是CR3或N；D是CR4或N；L1是-(CR7R7)m-；L2是-(CR7R7)n-；X，Z，R1，R2，R3，R4，R5和R6都在此定义。还披露了将此类化合物用作调节TNFα的调节剂的方法，以及包含此类化合物的药物组合物。这些化合物可用于治疗炎症和自身免疫性疾病。
• Inhibitors of CYP 17
  申请人：BOCK Mark G.

  公开号：US20100331326A1

  公开（公告）日：2010-12-30

  The present invention provides compounds of Formula (I) and (II), or a pharmaceutically acceptable salts thereof, where R 53 , R 54 , p, q, and n are as defined herein. The compounds of the present invention have been found to be useful as 17α-hydroxylase/C 17,20 -lyase inhibitors.

  本发明提供了式(I)和(II)的化合物，或其药用可接受的盐， 其中R 53 ，R 54 ，p，q和n如本文所述定义。本发明的化合物被发现作为17α-羟化酶/C 17,20 -裂解酶抑制剂是有用的。
• [EN] OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS<br/>[FR] DÉRIVÉS D'OXAZINE ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES NEUROLOGIQUES
  申请人：NOVARTIS AG

  公开号：WO2012095463A1

  公开（公告）日：2012-07-19

  The invention relates to novel heterocyclic compounds of the formula (I), in which all of the variables are as defined in the specification, in free form or in pharmaceutically acceptable salt form, to their preparation, to their medical use and to medicaments comprising them.

  本发明涉及式(I)的新杂环化合物，其中所有变量如说明书中所定义，以自由形式或药物可接受的盐形式存在，以及它们的制备、医学用途和包含它们的药物。